Medpage Today on MSN13h
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...
A diet of fruits and vegetables, whole grains, low-fat dairy foods and lean meats, low in salt and sugar, is associated with ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
The IFPA Forum 2025 will unite stakeholders from across the Americas to address the urgent challenges faced by individuals ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Your skin holds vital clues about your health. From thyroid issues to heart problems, discover what your skin is trying to ...
Having a sore and itchy scalp can be a complete pain, as the irritation is distracting and at times all-consuming - however ...
The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...
Zacks Investment Research on MSN17h
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback